

India

REDUCE (no change)

Buy 10 Hold 2 Sell 3 Consensus ratings*: Current price: Rs1.925 Rs1.460 Target price: Previous target: Rs1,745 -24.2% Up/downside: InCred Research / Consensus: -34.3% **DPNT.NS** Reuters: Bloombera: DN IN US\$3,228m Market cap: Rs262,618m US\$18.6m Average daily turnover: Rs1514.3m Current shares o/s: 136.4m Free float: 54.3% *Source: Bloomberg



Price performance	1M	ЗМ	12M
Absolute (%)	(7.8)	(14.3)	(27.4)
Relative (%)	(6.5)	(16.7)	(29.0)

Major shareholders	% held
Promoter & Promoter Group	45.7
Nippon Life India Ltd	3.3
Franklin India Smaller Companies Fund	3.2

Deepak Nitrite Ltd

Analyzing its probable polycarbonate project

- Our analysis of the global polycarbonate market and its spreads over bisphenol-A indicate that in an average case scenario, a 0.2mt capacity plant can make Rs12bn in gross profit.
- Please note that Deepak Nitrite (DNL) has not yet finalized this project, but currently DNL is evaluating it. (Source: DNL's post-results conference call).
- Polycarbonate market is heavily oversupplied and currently the industry's capacity utilization is ~70% with multiple capex (globally) in the pipeline. This project (if it fructifies) will increase the commodity chemicals nature of DNL.

Deepak Nitrite is contemplating setting up a polycarbonate plant

We quote from Deepak Nitrite's management commentary during the 1QFY23 results conference call: "Polycarbonate will again be a total downstream what we are talking. That has been our strategy, and we have been discussing this for quite some time. So, phenol downstream going up to polycarbonate, this is how we will grow. So, then obviously all these things will require around Rs6,500 crore to Rs7,000 crore based on current estimation." The capex part of the polycarbonate plant is still not clear and we believe that Rs60-70bn is the overall capex. However, going by the global standards, a 0.2mt plant can cost around US\$250m.

Polycarbonate is an oversupplied commodity

Global demand for polycarbonate is around 5mt whereas the global capacity is ~7.2mt and further capacity expansion is in the pipeline. With 75% of the demand for polycarbonate coming from consumer appliances, automotive and electronics sectors, polycarbonate is highly linked to the global demand cycle. In CY20, global demand for polycarbonate declined by 10%. We believe that CY22 demand was ~5mt. Global polycarbonate demand CAGR has been ~3% (over CY11-CY22).

Polycarbonate will only increase earnings volatility of Deepak Nitrite

The spreads of polycarbonate over bisphenol-A are highly volatile. Based on the average spreads of the last six years, a 0.2mt plant can add Rs12bn to gross profit. However, please note that even a 1SD variation can lead gross profit to be in the Rs24bn to Rs4bn range. At -1 SD plant won't make any EBITDA. Setting up a polycarbonate plant will only increase the commodity nature of Deepak Nitrite's business and hence, it will get a lower multiple.

Consensus EPS estimates too high and need a huge cut; REDUCE

Consensus EPS estimates of Deepak Nitrite are too high. FY23F, FY24F and FY25F EPS estimates need to be cut by 20%, 30% and 30%, respectively. The stock trades at a lofty valuation. We retain our REDUCE rating on it with a lower target price of Rs1,460 (Rs1,745 earlier). We have valued the stock at 20x FY25F EPS. Upside risk: Higher-than-estimated phenol spreads can lead to a higher price for the stock.

Analyst(s)



Satish KUMAR

T (91) 22 4161 1562

E satish.kumar@incredcapital.com

Abbas PUNJANI

T (91) 22 4161 1598

E abbas.punjani@incredcapital.com

Shaily RUPARELIA

T (91) 22 4161 1556

E shaily.ruparelia@incredcapital.com

Financial Summary	Mar-21A	Mar-22A	Mar-23F	Mar-24F	Mar-25F
Revenue (Rsm)	43,598	68,022	75,595	81,010	92,170
Operating EBITDA (Rsm)	12,470	16,036	12,799	13,796	15,478
Net Profit (Rsm)	7,758	10,666	8,097	8,823	9,946
Core EPS (Rs)	56.9	78.2	59.4	64.7	72.9
Core EPS Growth	27.0%	37.5%	(24.1%)	9.0%	12.7%
FD Core P/E (x)	33.85	24.62	32.44	29.77	26.41
DPS (Rs)	5.5	7.0	4.9	4.9	4.9
Dividend Yield	0.34%	0.44%	0.30%	0.30%	0.30%
EV/EBITDA (x)	21.30	16.27	20.55	19.03	16.91
P/FCFE (x)	323.48	221.41	187.26	298.29	155.90
Net Gearing	13.1%	(5.3%)	0.9%	(0.3%)	(1.5%)
P/BV (x)	11.19	7.87	6.46	5.39	4.54
ROE	39.6%	37.5%	21.9%	19.7%	18.7%
% Change In Core EPS Estimates			(18.78%)	(14.56%)	
InCred Research/Consensus EPS (x)					

SOURCE: INCRED RESEARCH, COMPANY REPORTS



Analyzing its probable polycarbonate project

In our earlier report of Jan 2022, we had analysed all the expansion projects of Deepak Nitrite. Please click the link for this report: <a href="IN: Deepak Nitrite Ltd - Deepak

Polycarbonate is a normal commodity


What is polycarbonate? ➤

Polycarbonate refers to a group of thermoplastic polymers containing carbonate groups in their chemical structures. Polycarbonate that is used in engineering is a strong, tough material and some grades are optically transparent. It can be easily worked upon, moulded, and thermoformed. Because of these properties, polycarbonate finds many applications.

How is polycarbonate produced? ➤


Most of the polycarbonate is produced through the reaction of bisphenol-A with phosgene gas. Please note that Deepak Nitrite is setting up a bisphenol-A plant and India is an importer of polycarbonate to the extent of ~150kt and hence, it's natural that the company is thinking of setting up a polycarbonate plant.

Global polycarbonate demand has been around 4.5mt ➤






Polycarbonate is primarily used in consumer applications >




SABIC, Covestro and Mitsubishi are the main players in global polycarbonate market; geography-wise, China dominates >

SABIC, Covestro and Mitsubishi are the main players in the global market. Given that phenol is the principal input material, which is manufactured from benzene and propylene, it's not surprising that SABIC is one of the major players with ~1.5mt capacity.






India has been a big importer of polycarbonate from Thailand and South Korea ➤



Polycarbonate spreads over bisphenol-A are highly volatile >




Adjusted for phosgene cost, a 0.2mt plant at full capacity can make Rs12bn in gross profit ➤

Adjusted for phosgene and other raw material cost, a 0.2mt plant can make Rs12 bn in gross profit. However, the standard deviation in gross profit is quite high, and it can range from Rs24bn to Rs4bn.



BY THE NUMBERS





(Rs mn)	Mar-21A	Mar-22A	Mar-23F	Mar-24F	Mar-25F
Total Net Revenues	43,598	68,022	75,595	81,010	92,170
Gross Profit	20,955	26,878	22,679	24,303	27,651
Operating EBITDA	12,470	16,036	12,799	13,796	15,478
Depreciation And Amortisation	(1,526)	(1,777)	(1,790)	(1,896)	(2,038)
Operating EBIT	10,944	14,259	11,009	11,900	13,440
Financial Income/(Expense)	(742)	(340)	(399)	(319)	(359)
Pretax Income/(Loss) from Assoc.					
Non-Operating Income/(Expense)	215	426	215	215	215
Profit Before Tax (pre-EI)	10,417	14,345	10,825	11,796	13,297
Exceptional Items					
Pre-tax Profit	10,417	14,345	10,825	11,796	13,297
Taxation	(2,659)	(3,678)	(2,728)	(2,973)	(3,351)
Exceptional Income - post-tax					
Profit After Tax	7,758	10,666	8,097	8,823	9,946
Minority Interests					
Preferred Dividends					
FX Gain/(Loss) - post tax					
Other Adjustments - post-tax					
Net Profit	7,758	10,666	8,097	8,823	9,946
Recurring Net Profit	7,758	10,666	8,097	8,823	9,946
Fully Diluted Recurring Net Profit	7,758	10,666	8,097	8,823	9,946

Cash Flow					
(Rs mn)	Mar-21A	Mar-22A	Mar-23F	Mar-24F	Mar-25F
EBITDA	12,470	16,036	12,799	13,796	15,478
Cash Flow from Invt. & Assoc.					
Change In Working Capital	(441)	(11,712)	(1,146)	(943)	(1,943)
(Incr)/Decr in Total Provisions					
Other Non-Cash (Income)/Expense	111	(89)			
Other Operating Cashflow	957	810	399	319	359
Net Interest (Paid)/Received	(742)	(340)	(399)	(319)	(359)
Tax Paid	(2,365)	3,535	(2,728)	(2,973)	(3,351)
Cashflow From Operations	9,990	8,238	8,925	9,880	10,184
Capex	(2,096)	(1,868)	(9,500)	(8,500)	(8,500)
Disposals Of FAs/subsidiaries	10	7			
Acq. Of Subsidiaries/investments	(1,854)	(2,401)			
Other Investing Cashflow	(21)	22			
Cash Flow From Investing	(3,962)	(4,241)	(9,500)	(8,500)	(8,500)
Debt Raised/(repaid)	(5,217)	(2,812)	1,977	(500)	
Proceeds From Issue Of Shares					
Shares Repurchased					
Dividends Paid	(4)	(750)	(800)	(800)	(800)
Preferred Dividends					
Other Financing Cashflow	(741)	(296)			
Cash Flow From Financing	(5,961)	(3,858)	1,177	(1,300)	(800)
Total Cash Generated	68	140	603	80	885
Free Cashflow To Equity	812	1,186	1,403	880	1,685
Free Cashflow To Firm	6,771	4,338	(176)	1,699	2,043

SOURCE: INCRED RESEARCH, COMPANY REPORTS

Chemicals - Overall | India Deepak Nitrite Ltd | January 21, 2023

BY THE NUMBERS...cont'd

Balance Sheet					
(Rs mn)	Mar-21A	Mar-22A	Mar-23F	Mar-24F	Mar-25F
Total Cash And Equivalents	2,202	4,786	4,635	4,611	5,352
Total Debtors	7,563	11,291	12,427	13,317	15,151
Inventories	3,827	5,846	7,249	7,768	8,838
Total Other Current Assets	1,175	1,183	1,183	1,183	1,183
Total Current Assets	14,767	23,105	25,493	26,879	30,524
Fixed Assets	20,596	20,857	28,703	35,307	41,769
Total Investments	25	22	22	22	22
Intangible Assets					
Total Other Non-Current Assets	214	321	321	321	321
Total Non-current Assets	20,836	21,200	29,046	35,650	42,112
Short-term Debt	31	1,132	2,484	2,484	2,484
Current Portion of Long-Term Debt					
Total Creditors	4,367	5,117	6,510	6,977	7,938
Other Current Liabilities	1,136	1,220	1,220	1,220	1,220
Total Current Liabilities	5,535	7,469	10,215	10,681	11,642
Total Long-term Debt	5,240	1,875	2,500	2,000	2,000
Hybrid Debt - Debt Component					
Total Other Non-Current Liabilities	111	129	129	129	129
Total Non-current Liabilities	5,352	2,004	2,629	2,129	2,129
Total Provisions	1,250	1,447	1,015	1,015	1,015
Total Liabilities	12,137	10,920	13,858	13,824	14,785
Shareholders Equity	23,467	33,384	40,681	48,705	57,851
Minority Interests					
Total Equity	23,467	33,384	40,681	48,705	57,851

Key Ratios					
	Mar-21A	Mar-22A	Mar-23F	Mar-24F	Mar-25F
Revenue Growth	3.1%	56.0%	11.1%	7.2%	13.8%
Operating EBITDA Growth	21.6%	28.6%	(20.2%)	7.8%	12.2%
Operating EBITDA Margin	28.6%	23.6%	16.9%	17.0%	16.8%
Net Cash Per Share (Rs)	(22.50)	13.04	(2.56)	0.93	6.36
BVPS (Rs)	172.04	244.75	298.25	357.07	424.12
Gross Interest Cover	14.75	41.89	27.61	37.33	37.47
Effective Tax Rate	25.5%	25.6%	25.2%	25.2%	25.2%
Net Dividend Payout Ratio	11.6%	10.7%	9.9%	9.1%	8.0%
Accounts Receivables Days	57.31	50.58	57.26	57.99	56.37
Inventory Days	62.64	42.90	45.16	48.33	46.97
Accounts Payables Days	64.56	42.07	40.10	43.40	42.19
ROIC (%)	30.5%	38.0%	24.8%	21.1%	20.2%
ROCE (%)	38.7%	42.3%	26.2%	23.7%	23.0%
Return On Average Assets	24.6%	27.3%	17.0%	15.5%	15.1%

SOURCE: INCRED RESEARCH, COMPANY REPORTS



Chemicals - Overall | India Deepak Nitrite Ltd | January 21, 2023

DISCLAIMER

This report (including the views and opinions expressed therein, and the information comprised therein) has been prepared by Incred Research Services Private Ltd.(formerly known as Earnest Innovation Partners Private Limited) (hereinafter referred to as "IRSPL"). IRSPL is registered with SEBI as a Research Analyst vide Registration No. INH000007793. Pursuant to a trademark agreement, IRSPL has adopted "Incred Equities" as its trademark for use in this report.

The term "IRSPL" shall, unless the context otherwise requires, mean IRSPL and its affiliates, subsidiaries and related companies. This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject IRSPL and its affiliates/group companies to registration or licensing requirements within such jurisdictions.

This report is being supplied to you strictly on the basis that it will remain confidential. No part of this report may be (i) copied, photocopied, duplicated, stored or reproduced in any form by any means; or (ii) redistributed or passed on, directly or indirectly, to any other person in whole or in part, for any purpose without the prior written consent of IRSPL.

The information contained in this report is prepared from data believed to be correct and reliable at the time of issue of this report.

IRSPL is not required to issue regular reports on the subject matter of this report at any frequency and it may cease to do so or change the periodicity of reports at any time. IRSPL is not under any obligation to update this report in the event of a material change to the information contained in this report. IRSPL has not any and will not accept any, obligation to (i) check or ensure that the contents of this report remain current, reliable or relevant; (ii) ensure that the content of this report constitutes all the information a prospective investor may require; (iii) ensure the adequacy, accuracy, completeness, reliability or fairness of any views, opinions and information, and accordingly, IRSPL and its affiliates/group companies (and their respective directors, associates, connected persons and/or employees) shall not be liable in any manner whatsoever for any consequences (including but not limited to any direct, indirect or consequential losses, loss of profits and damages) of any reliance thereon or usage thereof.

Unless otherwise specified, this report is based upon reasonable sources. Such sources will, unless otherwise specified, for market data, be market data and prices available from the main stock exchange or market where the relevant security is listed, or, where appropriate, any other market. Information on the accounts and business of company(ies) will generally be based on published statements of the company(ies), information disseminated by regulatory information services, other publicly available information and information resulting from our research. Whilst every effort is made to ensure that statements of facts made in this report are accurate, all estimates, projections, forecasts, expressions of opinion and other subjective judgments contained in this report are based on assumptions considered to be reasonable as of the date of the document in which they are contained and must not be construed as a representation that the matters referred to therein will occur. Past performance is not a reliable indicator of future performance. The value of investments may go down as well as up and those investing may, depending on the investments in question, lose more than the initial investment. No report shall constitute an offer or an invitation by or on behalf of IRSPL and its affiliates/group companies to any person to buy or sell any investments.

The opinions expressed are based on information which are believed to be accurate and complete and obtained through reliable public or other non-confidential sources at the time made. (Information barriers and other arrangements may be established where necessary to prevent conflicts of interests arising. However, the analyst(s) may receive compensation that is based on his/their coverage of company(ies) in the performance of his/their duties or the performance of his/their recommendations. In reviewing this report, an investor should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additional information is, subject to the duties of confidentiality, available on request. The report is not a "prospectus" as defined under Indian Law, including the Companies Act, 2013, and is not, and shall not be, approved by, or filed or registered with, any Indian regulator, including any Registrar of Companies in India, SEBI, any Indian stock exchange, or the Reserve Bank of India. No offer, or invitation to offer, or solicitation of subscription with respect to any such securities listed or proposed to be listed in India is being made, or intended to be made, to the public, or to any member or section of the public in India, through or pursuant to this report.

The research analysts, strategists or economists principally responsible for the preparation of this research report are segregated from the other activities of IRSPL. Information barriers and other arrangements have been established, as required, to prevent any conflicts of interests.

The research analysts, strategists or economists principally responsible for the preparation of this research report are segregated from the other activities of IRSPL. Information barriers and other arrangements have been established, as required, to prevent any conflicts of interests.

IRSPL may have issued other reports (based on technical analysis, event specific, short term views etc.) that are inconsistent with and reach different conclusion from the information presented in this report.

Holding of Analysts/Relatives of Analysts, IRSPL and Associates of IRSPL in the covered securities, as on the date of publishing of this report



Chemicals - Overall | India Deepak Nitrite Ltd | January 21, 2023

	Analyst/ Relative	Entity/ Associates
any financial interests in the company covered in this report (subject company) and nature of such financial interest	NO	NO
actual/beneficial ownership of 1% or more in securities of the subject company at the end of the month immediately preceding the date of publication of the research report or date of the public appearance;	NO	NO
any other material conflict of interest at the time of publication of the research report or at the time of public appearance	NO	NO
received any compensation from the subject company in the past twelve months for investment banking or merchant banking or brokerage services or investment advisory or depository or distribution from the subject company in the last twelve months for products/services other than investment banking or merchant banking or broker- age services or investment advisory or depository or distribution from the subject company in the last twelve months	NO	NO
managed or co-managed public offering of securities for the subject company in the last twelve months	NO	NO
received any compensation or other benefits from the subject company or third party in connection with the research report	NO	NO
served as an officer, director or employee of the subject company	NO	NO
been engaged in market making activity for the subject company	NO	NO

Analyst declaration

- The analyst responsible for the production of this report hereby certifies that the views expressed herein accurately and exclusively reflect his
 or her personal views and opinions about any and all of the issuers or securities analysed in this report and were prepared independently and
 autonomously in an unbiased manner.
- No part of the compensation of the analyst(s) was, is, or will be directly or indirectly related to the inclusion of specific recommendations(s) or view(s) in this report or based any specific investment banking transaction.
- The analyst(s) has(have) not had any serious disciplinary action taken against him/her(them).
- The analyst, strategist, or economist does not have any material conflict of interest at the time of publication of this report.
- The analyst(s) has(have) received compensation based upon various factors, including quality, accuracy and value of research, overall firm performance, client feedback and competitive factors.

IRSPL and/or its affiliates and/or its Directors/employees may own or have positions in securities of the company(ies) covered in this report or any securities related thereto and may from time to time add to or dispose of, or may be materially interested in, any such securities.

IRSPL and/or its affiliates and/or its Directors/employees may do and seek to do business with the company(ies) covered in this research report and may from time to time (a) buy/sell the securities covered in this report, from time to time and/or (b) act as market maker or have assumed an underwriting commitment in securities of such company(ies), and/or (c) may sell them to or buy them from customers on a principal basis and/or (d) may also perform or seek to perform significant investment banking, advisory, underwriting or placement services for or relating to such company(ies) and/or (e) solicit such investment, advisory or other services from any entity mentioned in thisreport and/or (f) act as a lender/borrower to such company and may earn brokerage or other compensation. However, Analysts are forbidden to acquire, on their own account or hold securities (physical or uncertificated, including derivatives) of companies in respect of which they are compiling and producing financial recommendations or in the result of which they play a key part.